Search

Displaying results 2041 - 2050 of 10000 in total
  1. Drug

    Obinutuzumab

    go.drugbank.com/drugs/DB08935
    ApprovedInvestigational

    [L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis. … This chemical modification significantly enhances its affinity for FcγRIII receptors on immune effector cells.

  2. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection … It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  3. Drug

    Spectinomycin

    go.drugbank.com/drugs/DB00919
    ApprovedVet approvedWithdrawn

    An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

  4. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking.

  5. Drug

    Fesoterodine

    go.drugbank.com/drugs/DB06702
    Approved

    Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

  6. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost. … In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone.

  7. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    FDA approved in December 2008. Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.

  8. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.

  9. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

  10. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. … Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997.